Get the Stockscreener App
0.7967
0.86%
-0.0069
After Hours:
.82
0.0233
+2.92%
Xilio Therapeutics Inc stock is traded at $0.7967, with a volume of 777.44K.
It is down -0.86% in the last 24 hours and down -5.46% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
See More
Previous Close:
$0.8036
Open:
$0.828
24h Volume:
777.44K
Relative Volume:
1.21
Market Cap:
$41.29M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2692
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
+0.85%
1M Performance:
-5.46%
6M Performance:
+4.05%
1Y Performance:
-37.27%
1-Day Range:
$0.7714
$0.828
1-Week Range:
$0.7714
$0.8989
52-Week Range:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.7967 | 41.65M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
What machine learning models say about Xilio Therapeutics Inc.Weekly Trend Report & AI Driven Stock Price Forecasts - newser.com
What Fibonacci levels say about Xilio Therapeutics Inc. reboundJuly 2025 Levels & Weekly High Return Opportunities - newser.com
Why Xilio Therapeutics Inc. stock remains on watchlistsJuly 2025 Action & Community Consensus Picks - newser.com
Using data models to predict Xilio Therapeutics Inc. stock movementJuly 2025 Pullbacks & Short-Term Swing Trade Alerts - newser.com
Why Xilio Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Fed Impact & Community Consensus Picks - newser.com
Why analysts remain bullish on Xilio Therapeutics Inc. stockLong Setup & Accurate Buy Signal Alerts - newser.com
How Xilio Therapeutics Inc. stock performs in high volatility marketsEarnings Risk Report & Fast Entry High Yield Stock Tips - newser.com
Can Xilio Therapeutics Inc. stock deliver sustainable ROEMarket Weekly Review & Expert Curated Trade Ideas - newser.com
Volume spikes in Xilio Therapeutics Inc. stock – what they meanTreasury Yields & Real-Time Volume Triggers - newser.com
Will Xilio Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Spike Watch & Real-Time Volume Spike Alerts - newser.com
Tools to assess Xilio Therapeutics Inc.’s risk profile2025 Trading Volume Trends & Real-Time Market Trend Scan - newser.com
Xilio to present vilastobart phase 2 data at SITC annual meeting - Investing.com Australia
How Xilio Therapeutics Inc. stock compares to market leadersJuly 2025 EndofMonth & Pattern Based Trade Signal System - newser.com
Best data tools to analyze Xilio Therapeutics Inc. stockMarket Weekly Review & Free High Accuracy Swing Entry Alerts - newser.com
What the charts say about Xilio Therapeutics Inc. todaySwing Trade & Technical Pattern Based Buy Signals - newser.com
Volatility clustering patterns for Xilio Therapeutics Inc.July 2025 Catalysts & Smart Investment Allocation Insights - newser.com
Is Xilio Therapeutics Inc. stock safe for conservative investorsWeekly Profit Recap & Verified Momentum Stock Watchlist - newser.com
Is Xilio Therapeutics Inc. stock a buy before product launchesQuarterly Profit Review & Safe Investment Capital Preservation Plans - newser.com
How geopolitical tensions affect Xilio Therapeutics Inc. stockInsider Buying & Technical Entry and Exit Tips - newser.com
What makes Xilio Therapeutics Inc. stock attractive to growth funds2025 Price Targets & Community Consensus Picks - newser.com
Xilio to present vilastobart phase 2 data at SITC annual meeting By Investing.com - Investing.com South Africa
Xilio (Nasdaq: XLO) late-breaking Phase 2 vilastobart poster at SITC on MSS mCRC, high pTMB - Stock Titan
Published on: 2025-10-30 02:53:37 - newser.com
Published on: 2025-10-28 23:16:50 - newser.com
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):